Humanized mice for innovative medicine Company features Erwan CORCUFF (Co-founder, CEO) Nicolas LEGRAND (CSO, Project manager) CIFFRE PhD student Antoine BERET (Co-founder, Chairman of board) Georges AZAR (Project manager) Salomé DUPONT (Master student) James DI SANTO (Co-founder, Scientific advisor) Nicolas GAIDOT (Research engineer) Flora SAINT CHARLES (Research engineer) Ai Ing LIM (ITN Homin) • Founded May 2010, spin-off Institut Pasteur • Location Center for Integrative Biology of Emerging Diseases (BIME) Institut Pasteur – Paris, France • Available products humanized mice as pre-clinical models in immunology, oncology, toxicology & infectious diseases “Human Immune System” mice for biomedical research GENETIC Human DNA HUMANIZATION “Human Immune System” (HIS) mice Immuno-deficient mice Mice humanized for cellular and molecular components of the immune system XENOGRAFT HUMANIZATION Human hematopoietic cells Optimized work flow to meet industrial needs Humanization Human cells Human Immune System mice Quality Quantity Reproductibility Predictibility Testing Immuno-deficient mice Custom made models • lead compound screening (safety and efficacy) • immuno-modulation • candidate vaccines • adjuvants • etc. • specific models for specific questions • for primary tumors, selected pathogens • available for co-development studies Human immunoprofiling • Characterization of human immune effector cell population • Assessment of drug activity $684M are wasted yearly on failed vaccines due to low predictability of animal tests Vaccine Development Process Discovery ($450M) Animal Testing Human Testing ($720M) FDA/Ap proval ($90M) 5% pass vaccines pass 95% fail 684M$ spent and wasted 5 Scientific strategy for development of AXENIS portfolio Vaccine development Infectious diseases Human Immune System mice Mice humanized for cellular and molecular components of the immune system Host-tumor interactions CONFIDENTIAL Human mAb discovery Inflammation 6 7 Humanized mice for innovative medicine YOUR PARTNER FOR: AXENIS S.A.S. • Human immuno-profiling for drug discovery and validation; CENTER FOR INTEGRATIVE BIOLOGY OF EMERGING DISEASES (BIME) • Services in pre-clinical testing and R&D; • Searching for and validating predictive biomarkers of disease progression or resolution (infection, autoimmunity, tumor control…); • Immunotoxicity of vaccine, biologicals, adjuvants and mAb treatments; • Development and validation of novel immunotherapies; • Unique innovative solutions and expertise for research, including infectious diseases; 28, RUE DU DOCTEUR ROUX 75015 PARIS FRANCE ERWAN CORCUFF (CEO) +33 1 45 68 80 74 [email protected] NICOLAS LEGRAND (CSO) +33 1 40 61 36 31 [email protected] small molecules,